BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ATV-1601 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ATV-1601\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07601425-9127@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:ATV-1601: Phase 1/2 readout est. (NCT07601425)
DESCRIPTION:ATV-1601\, phase 1/2.\nStudy: Harmony-HHT: ATV-1601 in Particip
 ants With Hereditary Hemorrhagic Telangiectasia (HHT)\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atv-1601#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07601425
URL:https://assetmemo.bio/drug/atv-1601#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038369-9127@assetmemo.bio
DTSTAMP:20261121T005446Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:ATV-1601: Phase 1 readout est. (NCT07038369)
DESCRIPTION:ATV-1601\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\nStudy
 : A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have A
 KT1 E17K Mutations\nEstimated primary completion: 31 August 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/atv-1601#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07038369
URL:https://assetmemo.bio/drug/atv-1601#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
